Search Results - "Hoyt, Kim"

51214 Deucravacitinib efficacy in palmoplantar and fingernail psoriasis by baseline Psoriasis Area and Severity Index (PASI) and baseline body surface area (BSA) in the phase 3 POETYK PSO-1 and PSO-2 trials by Elewski, Boni, Lambert, Jo, Merola, Joseph F., Lebwohl, Mark, Hoyt, Kim, Kisa, Renata M., Banerjee, Subhashis, Scharnitz, Thomas, Cather, Jennifer

Get full text

P096 Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in moderate-to-severe plaque psoriasis: safety profile in older (≥ 65 years) and younger (< 65 years) patients in the phase III POETYK PSO-1, PSO-2 and long-term extension trials by Kearney, Niamh, Pink, Andrew, Hoyt, Kim, Kisa, Renata M, Banerjee, Subhashis, Rogers, Alexandra, Mullan, Jill, Warren, Richard B

“…Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is approved in the USA, EU, UK and other countries for the treatment of…”
Get full text

51109 Efficacy of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in scalp psoriasis by baseline Psoriasis Area and Severity Index (PASI) and baseline body surface area (BSA): A subanalysis of the phase 3 clinical trial data by Blauvelt, Andrew, Sofen, Howard, Lambert, Jo, Merola, Joseph F., Lebwohl, Mark, Hoyt, Kim, Kisa, Renata M., Banerjee, Subhashis, Scharnitz, Thomas, Crowley, Jeffrey J.

Get full text

51091 Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in plaque psoriasis: 3-year Psoriasis Area and Severity Index (PASI) outcomes in the long-term extension of the phase 3 POETYK PSO-1 and PSO-2 trials by Gold, Linda Stein, Banerjee, Subhashis, Colombo, Matthew J., Kisa, Renata M., Berger, Victoria, Hoyt, Kim, Soung, Jennifer, Torres, Tiago, Bhatia, Neal, Glick, Brad P., Kaufmann, Mark D.

Get full text

51101 Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in moderate to severe plaque psoriasis: efficacy by baseline static Physician Global Assessment (sPGA) in two phase 3 trials by Sobell, Jeffrey M., Elewski, Boni, Seo, Seong Jun, Banerjee, Subhashis, Balagula, Eugene, Scharnitz, Thomas, Hoyt, Kim, Yamauchi, Paul, Bettencourt, Miriam, Cameron, Michael C., Lebwohl, Mark

Get full text

Visual performance with a daily disposable contact lens compared to best corrected sphero-cylindrical spectacle refraction by Coles-Brennan, Chantal, Hoyt, Kim, Moody, Kurt

Get full text

Efficacy of Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Scalp Psoriasis by Baseline Psoriasis Area and Severity Index (PASI) and Baseline Body Surface Area (BSA): A Subanalysis of the Phase 3 Clinical Trial Data by Blauvelt, Andrew, Sofen, Howard, Lambert, Jo, Merola, Joseph F., Lebwohl, Mark, Hoyt, Kim, Banerjee, Subhashis, Scharnitz, Thomas, Crowley, Jeffrey J.

“…Introduction: Deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, is approved in the US, EU, and other countries for treatment of adults with…”
Get full text

Deucravacitinib in moderate to severe plaque psoriasis: liver transaminase results from the phase 3 POETYK PSO program by Lebwohl, Mark, Egeberg, Alexander, Linaberry, Misti, Hoyt, Kim, Banerjee, Subhashis, Kisa, Renata M., Strober, Bruce

“…Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is approved by the US Food and Drug Administration for the…”
Get full text

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: evaluation of lipid parameters in the phase 3 POETYK PSO-1 and PSO-2 trials by Lebwohl, Mark, Strober, Bruce, Linaberry, Misti, Hoyt, Kim, Banerjee, Subhashis, Kisa, Renata M., Mehta, Nehal N.

“…Introduction: Tyrosine kinase 2 (TYK2), an intracellular kinase, mediates signaling of cytokines (IL-23 and Type I interferons) involved in psoriasis…”
Get full text

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Evaluation of Creatine Phosphokinase Elevations in the Phase 3 POETYK PSO-1 and PSO-2 Trials by Lebwohl, Mark, Strober, Bruce, Scharnitz, Thomas, Linaberry, Misti, Hoyt, Kim, Banerjee, Subhashis, Kisa, Renata M., Martin, George

“…Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the US, EU, and other countries for the treatment of…”
Get full text

Deucravacitinib Long-term Efficacy Through 4 Years in Week 16 Placebo Crossover Patients in the Phase 3 POETYK PSO-1, PSO-2, and LTE Program by Lebwohl, Mark, Warren, Richard B., Imafuku, Shinichi, Bagel, Jerry, Armstrong, April W., Passeron, Thierry, Banerjee, Subhashis, Colombo, Matthew J., Scharnitz, Thomas, Hoyt, Kim, Thaçi, Diamant, Blauvelt, Andrew

“…Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the US, EU, and other countries for treatment of…”
Get full text

Tear Film Metric Derived from Twyman-Green Interferometry of Tear Films by Hofmann, Greg, Coles-Brennon, Chantal, Hoyt, Kim, Cheng, Xu, Buch, John, Cannon, Jessica, Fadli, Zohra

Get full text

Deucravacitinib Long-Term Efficacy Through 4 years in Week 16 Placebo Crossover Patients in the Phase 3 POETYK PSO-1, PSO-2, and LTE Program by Lebwohl, Mark, Warren, Richard B., Imafuku, Shinichi, Bagel, Jerry, Armstrong, April W., Passeron, Thierry, Banerjee, Subhashis, Colombo, Matthew J., Scharnitz, Thomas, Hoyt, Kim, Thaci, Diamant, Blauvelt, Andrew

“…Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the US, EU, and other countries for treatment of…”
Get full text

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: efficacy by baseline body surface area (BSA) involvement and baseline Psoriasis Area and Severity Index (PASI) by Armstrong, April W., Lebwohl, Mark, Bagel, Jerry, Schlesinger, Todd, Banerjee, Subhashis, Kisa, Renata M., Scharnitz, Thomas, Hoyt, Kim, Strober, Bruce

Get full text

Deucravacitinib in Moderate Plaque Psoriasis: Efficacy in the Phase 3 POETYK PSO-1 and PSO-2 Trials by Blauvelt, Andrew, Korman, Neil J., Merola, Joseph F., Gooderham, Melinda, Balagula, Eugene, Vanlandingham, Rebecca, Treitel, Michelle, Wittstock, Keith, Hoyt, Kim, Banerjee, Subhashis, Desai, Seemal R.

“…Introduction: Deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, was efficacious and well tolerated in adults with moderate to severe plaque…”
Get full text

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Body Surface Area (BSA) Involvement and Baseline Psoriasis Area and Severity Index (PASI) by Sobell, Jeffrey M., Elewski, Boni, Banerjee, Subhashis, Balagula, Eugene, Scharnitz, Thomas, Berger, Victoria, Hoyt, Kim, Yamauchi, Paul, Bettencourt, Miriam, Cameron, Michael C., Lebwohl, Mark

“…Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the US, EU, and other countries for the treatment of…”
Get full text

Deucravacitinib Long-term Efficacy With Continuous Treatment in Plaque Psoriasis: 2-Year Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials by Thaçi, Diamant, Lebwohl, Mark, Warren, Richard B., Kircik, Leon, Banerjee, Subhashis, Napoli, Andrew, Kisa, Renata M., Linaberry, Misti, Hoyt, Kim, Blauvelt, Andrew

“…Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the US, EU, and other countries for the treatment of…”
Get full text

Deucravacitinib in Plaque Psoriasis: Laboratory Parameters Through 4 Years of Treatment in the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials by Korman, Neil J., Passeron, Thierry, Okubo, Yukari, Bagel, Jerry, Warren, Richard B., Spelman, Lynda, Winthrop, Kevin, Hoyt, Kim, Scharnitz, Thomas, Banerjee, Subhashis, Thaçi, Diamant, Shahriari, Mona, Stein Gold, Linda

“…Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in multiple countries for treatment of adults with…”
Get full text

Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 4 Years in the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials by Strober, Bruce, Imafuku, Shinichi, Paul, Carle, Gooderham, Melinda, Spelman, Lynda, Seo, Seong Jun, Passeron, Thierry, Hoyt, Kim, Colombo, Matthew J., Banerjee, Subhashis, Augustin, Matthias, Stein Gold, Linda, Alexis, Andrew F., Thaci, Diamant, Lebwohl, Mark, Issa, Naiem T., Cameron, Michael C.

“…Introduction: Deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, was superior to placebo and apremilast in two global, phase 3 trials (POETYK…”
Get full text

Deucravacitinib Long-Term Efficacy in Week 16 Placebo Crossovers: 3-year Results from the POETYK PSO Program by Lebwohl, Mark, Warren, Richard B., Imafuku, Shinichi, Bagel, Jerry, Armstrong, April W., Passeron, Thierry, Banerjee, Subhashis, Kisa, Renata M., Vritzali, Eleni, Colombo, Matthew J., Scharnitz, Thomas, Hoyt, Kim, Thaçi, Diamant, Blauvelt, Andrew

“…Introduction: Deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, is approved in the US, EU, and other countries for treatment of adults with…”
Get full text